Latest filing published 29 Jul 2026 for Viking Therapeutics, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Marianna Mancini (senior executive) discloses dealings in Viking Therapeutics, Inc. to SEC (Form 4). Over a trading history stretching from 28 September 2021 to 29 July 2026, the count stands at 19 filings.
No open-market purchase appears, only 1 sale worth €535k. Other entries cover 14 share grants and 4 option exercises. 2026 to date brings no purchases and 1 sale.
On 29 July 2026 came the latest disclosure, a share grant in Viking Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
19 of 19 declarations